<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04235556</url>
  </required_header>
  <id_info>
    <org_study_id>APHP190973</org_study_id>
    <nct_id>NCT04235556</nct_id>
  </id_info>
  <brief_title>Integrated Care Pathway in Oncology (PASSION)</brief_title>
  <acronym>PASSION</acronym>
  <official_title>Integrated Management of Care Pathway in Oncology. Impact on the Delay of Therapeutic Management and the Satisfaction of Patients and Carers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>MSD France</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A centralized unit for integrated management of care pathway in Oncology has been created.
      This unit settles the patients' appointments (biopsy, intravenous device, chemotherapy,
      imaging, oncologist...).

      The aim of this study is to assess the delay between the first appointment with the
      oncologist and the beginning of the antitumoral treatment, and therefore evaluate the
      efficacy of the care pathway unit.

      The second aim is to assess the satisfaction of patients and health care teams.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PASSION is a french monocentric study.

      For the retrospective cohort, patient will be selected through the use of data warehouse
      available on the HEGP.

      For the prospective cohort, patient will be included according to the selection criteria.

      Each patient will be followed up during 6 month and a satisfaction questionnaire will be
      completed at 1 month and 4 month of the first administration of anti-tumor therapy.

      For both cohort, clinical-anatomo-biological data will be collected through the use of data
      warehouse available on the HEGP.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 21, 2020</start_date>
  <completion_date type="Anticipated">February 28, 2021</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Time between the first appointment with the oncologist and the beginning of antitumoral treatment.</measure>
    <time_frame>6 months</time_frame>
    <description>Delay of health care</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patients satisfaction</measure>
    <time_frame>6 months</time_frame>
    <description>Satisfaction of patients with OUT-PATSAT35 questionnaire (out-patient satisfaction) : Likert type scale with 5 ordered modalities (bad to excellent), rated from 1 to 5.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health care teams satisfaction</measure>
    <time_frame>6 months</time_frame>
    <description>Satisfaction of health care teams : qualitative questionnaire with 4 ordered modalities (very satisfied to not satisfied)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of emergency consultations and hospitalizations</measure>
    <time_frame>6 months</time_frame>
    <description>Need for unexpected health care</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">1800</enrollment>
  <condition>Colon Cancer</condition>
  <condition>Gastric Cancer</condition>
  <condition>Pancreatic Cancer</condition>
  <condition>Thoracic Neoplasms</condition>
  <condition>Breast Cancer</condition>
  <condition>Ovarian Cancer</condition>
  <condition>Bladder Cancer</condition>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Historic cohort</arm_group_label>
    <description>Retrospective cohort of patients that were treated in the Hôpital Européen Georges Pompidou before the creation of the care pathway unit.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prospective cohort</arm_group_label>
    <description>All consecutive patients that meet the inclusion criterion and will begin a cancer care after the study start.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Care pathway unit</intervention_name>
    <description>Patients from the prospective cohort will have their health care scheduled by the care pathway unit.</description>
    <arm_group_label>Prospective cohort</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Retrospective cohort: patients treated at the Hôpital Européen Georges Pompidou in 2015 and
        2017.

        Prospective cohort:

          -  Histologically proven : colon, gastric, pancreatic, prostate, bladder, breast,
             thoracic, or ovarian cancer

          -  First appointment for cancer care at the Hôpital Européen Georges Pompidou

          -  Ile de France resident

          -  All appointments planned at the Hôpital Européen Georges Pompidou

          -  Intravenous antitumoral treatment
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically proven : colon, gastric, pancreatic, prostate, bladder, breast,
             thoracic, or ovarian cancer

          -  First appointment for cancer care at the Hôpital Européen Georges Pompidou

          -  Intravenous antitumoral treatment

        Exclusion Criteria:

          -  Medical care non covered by social welfare

          -  Radiochemotherapy

          -  Death in the 6 months following first oncological appointment or absence of medical
             care in the year following the first oncological appointment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Virginie Bichon</last_name>
    <role>Principal Investigator</role>
    <affiliation>AP-HP, Hôpital Européen Georges Pompidou, Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Virginie Bichon</last_name>
    <phone>+33156095782</phone>
    <email>virginie.bichon@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gilles Chatellier, MD,PhD</last_name>
    <phone>+33156092026</phone>
    <email>gilles.chatellier@aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>AP-HP Hôpital européen Georges-Pompidou</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Virginie Bichon</last_name>
      <phone>+33156095782</phone>
      <email>virginie.bichon@aphp.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>December 2, 2019</study_first_submitted>
  <study_first_submitted_qc>January 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 22, 2020</study_first_posted>
  <last_update_submitted>March 4, 2020</last_update_submitted>
  <last_update_submitted_qc>March 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>care pathway</keyword>
  <keyword>satisfaction</keyword>
  <keyword>oncology</keyword>
  <keyword>treatment delay</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thoracic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>one year after the last publication</ipd_time_frame>
    <ipd_access_criteria>Data sharing must be accepted by the sponsor and the PI based on scientific project and scientific involvement of the PI team.
Teams wishing obtain IPD must meet the sponsor and IP team to present scientifics (and commercial) purpose, IPD needed, format of data transmission, and timeframe. Technical feasibility and financial support will be discussed before mandatory contractualization</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

